Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22479361 | 0.84 | GPR119 (0.42) | GPR119HPGDRECQL | |
| SCHEMBL18429017 | 0.83 | GPR119 (0.49) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL5244191 | 0.81 | JAK2 (0.55) | GPR119 | |
| SCHEMBL15410506 | 0.79 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL19964430 | 0.79 | GPR119 (0.53) | GPR119HPGDEPHX1 | |
| SCHEMBL13811514 | 0.77 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL13086399 | 0.77 | GPR119 (0.54) | GPR119HPGD | |
| SCHEMBL27589266 | 0.76 | EPHX1 (0.42) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL4402979 | 0.75 | HPGD (0.54) | GPR119HPGDRECQLEPHX1 | |
| SCHEMBL1308361 | 0.75 | GPR119 (0.58) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7238694-B2 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1723150-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005070941-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | GPR119 3424/4885HPGD 1984/4885TGM2 1837/4885 |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | RIF1, TOP1, TOP2A | GPR119 4144/4885HPGD 1058/4885TGM2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.